UNASSIGNED: A cutaneous @entity3 is relatively rare, and @entity1 with such a @entity5 usually have a poor prognosis. Even if the @entity3 can be treated, the treatment cannot improve the prognosis. However, neglecting metastatic lesions sometimes results in a great deterioration of quality of life. Cutaneous metastatic foci are generally treated with chemotherapy and/or radiotherapy. On the other hand, surgical treatment is sometimes chosen for cutaneous @entity3 . In this study, we analyzed data for 40 @entity1 with cutaneous @entity3 who received surgical treatment at Shizuoka @entity5 Center between January 2009 and August 2014. Among these cases, @entity2 was the most common primary @entity5 and the craniocervical region was the most frequent metastatic site. Among the @entity1 who died, the average duration to @entity204 after the operation was 186  days. We consider that resection of cutaneous @entity3 as palliative therapy is an appropriate therapeutic option if the @entity1 's condition permits resection. Such treatment can improve quality of life for both the @entity1 and their families.

Palliative surgical treatment for cutaneous XXXX is a valid option for improvement of quality of life.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'Cancer'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic tumors', 'metastases', 'metastatic tumor'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity3 :: (MESH:D009362,Disease) :: ['metastatic tumor']
